Risk assessment of substance use disorders based on the human leukocyte antigen (HLA).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 05 2023
26 05 2023
Historique:
received:
13
03
2023
accepted:
16
05
2023
medline:
29
5
2023
pubmed:
27
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
Substance use disorders (SUDs) are common and costly conditions that are partially attributable to genetic factors. In light of immune system influences on neural and behavioral aspects of addiction, the present study evaluated the influence of genes involved in the human immune response, human leukocyte antigen (HLA), on SUDs. We used an immunogenetic epidemiological approach to evaluate associations between the population frequencies of 127 HLA alleles and the population prevalences of six SUDs (alcohol, amphetamine, cannabis, cocaine, opioid, and "other" dependence) in 14 countries of Continental Western Europe to identify immunogenetic profiles of each SUD and evaluate their associations. The findings revealed two primary groupings of SUDs based on their immunogenetic profiles: one group comprised cannabis and cocaine, whereas the other group comprised alcohol, amphetamines, opioids, and "other" dependence. Since each individual possesses 12 HLA alleles, the population HLA-SUD scores were subsequently used to estimate individual risk for each SUD. Overall, the findings highlight similarities and differences in immunogenetic profiles of SUDs that may influence the prevalence and co-occurrence of problematic SUDs and may contribute to assessment of SUD risk of an individual on the basis of their HLA genetic makeup.
Identifiants
pubmed: 37237010
doi: 10.1038/s41598-023-35305-2
pii: 10.1038/s41598-023-35305-2
pmc: PMC10220069
doi:
Substances chimiques
HLA Antigens
0
Cocaine
I5Y540LHVR
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8545Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Arch Gen Psychiatry. 1998 Nov;55(11):967-72
pubmed: 9819064
J Mol Neurosci. 2013 Mar;49(3):574-81
pubmed: 22890421
Am J Psychiatry. 2003 Apr;160(4):687-95
pubmed: 12668357
Alcohol Clin Exp Res. 2016 Aug;40(8):1633-40
pubmed: 27388583
Neurosci Biobehav Rev. 2021 May;124:358-369
pubmed: 33556390
Ann N Y Acad Sci. 2021 Apr;1489(1):3-16
pubmed: 32147860
Annu Rev Genomics Hum Genet. 2013;14:301-23
pubmed: 23875801
World J Gastroenterol. 2007 Mar 28;13(12):1770-87
pubmed: 17465466
Addict Biol. 2013 Mar;18(2):286-96
pubmed: 22862835
Pharmacol Biochem Behav. 2005 Jun;81(2):396-406
pubmed: 15925401
Nucleic Acids Res. 2011 Jan;39(Database issue):D913-9
pubmed: 21062830
JAMA Psychiatry. 2015 Aug;72(8):757-66
pubmed: 26039070
BMC Res Notes. 2015 Jun 13;8:240
pubmed: 26070312
Curr Genomics. 2007 Nov;8(7):453-65
pubmed: 19412418
Arch Gen Psychiatry. 2007 Nov;64(11):1313-20
pubmed: 17984400
Pharmacogenomics J. 2018 May 22;18(3):398-405
pubmed: 28696413
Nature. 1970 Aug 1;227(5257):520-1
pubmed: 5428476
Nat Rev Immunol. 2018 May;18(5):325-339
pubmed: 29292391
Lancet Psychiatry. 2018 Dec;5(12):987-1012
pubmed: 30392731
Sci Adv. 2018 Mar 14;4(3):eaap7388
pubmed: 29546241
Brain Behav Immun. 2021 Jan;91:731-739
pubmed: 33031918
Malar J. 2014 Sep 03;13:349
pubmed: 25187124
Alcohol Alcohol. 1994 Nov;29(6):757-64
pubmed: 7695795
Nat Neurosci. 2012 Jan 26;15(2):181-9
pubmed: 22281715
Pharmacol Ther. 2013 Aug;139(2):289-300
pubmed: 23631821
J Neuroimmune Pharmacol. 2011 Mar;6(1):130-41
pubmed: 20440572
Hepatogastroenterology. 1988 Apr;35(2):65-8
pubmed: 3259529
Psychol Med. 2021 Oct;51(13):2189-2200
pubmed: 33879270
Neuropharmacology. 2022 Apr 1;207:108948
pubmed: 35032495